Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5 Febuxostat Purità Intermedja > 99.0% Fabbrika
Ruifu Chemical Supply Febuxostat Intermedji Relatati:
Febuxostat CAS 144060-53-7
Ethyl 2-Chloroacetoacetate CAS 609-15-4
4-Hydroxythiobenzamide CAS 25984-63-8
Ethyl 2-(3-Cyano-4-Hydroxyphenyl)-4-Methyl-1,3-Thiazole-5-Carboxylate CAS 161798-02-3
Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylate CAS 160844-75-7
Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-01-2
Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-03-4
Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5
Isem Kimiku | Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate |
Sinonimi | Febuxostat Intermedju |
Numru CAS | 161797-99-5 |
Numru tal-KAT | RF-PI1122 |
Status tal-istokk | Fil-Ħażna, Kapaċità tal-Produzzjoni 100 Tunnellata/Sena |
Formula Molekulari | C13H13NO3S |
Piż Molekulari | 263.31 |
Punt tat-tidwib | 180℃ |
Brand | Ruifu Kimika |
Oġġett | Speċifikazzjonijiet |
Dehra | Trab Isfar ċar għal Off-White |
Identifikazzjoni | Permezz HPLC;Minn HNMR |
Telf fuq Tnixxif | <0.50% |
Residwu fuq Ighition | <0.30% |
Impurità Unika | <0.50% |
Impuritajiet Totali | <1.00% |
Purità / Metodu ta 'Analiżi | >99.0% (mill-HPLC) |
Standard tat-Test | Standard tal-Intrapriża |
Użu | Intermedju ta' Febuxostat (CAS: 144060-53-7) |
Pakkett: Flixkun, borża tal-fojl tal-aluminju, 25kg/Drum tal-Kartun, jew skont il-ħtieġa tal-klijent
Kundizzjoni tal-Ħżin:Aħżen f'kontenituri ssiġillati f'post frisk u niexef;Ipproteġi mid-dawl u l-umdità
Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate (CAS: 161797-99-5) jintuża fis-sintesi ta 'Febuxostat (CAS: 144060-53-7), inibitur ta' xanthine oxidase/xanthine dehydrogenase.Użat għat-trattament ta 'iperuriċemija u gotta kronika.40-120 mg/jum febuxostat ġie ppruvat effettiv fit-tnaqqis tal-livelli ta' urat fis-serum meta ingħata biex jimmaniġġja l-iperuriċemija f'pazjenti bil-gotta.Fabuxostat ġie skopert minn Teijin Pharmaceuticals u liċenzjat lil TAP Pharmaceuticals (li bħalissa hija parti minn Takeda Pharmaceuticals) u ġie approvat fl-Istati Uniti għat-trattament tal-iperuriċemja f'pazjenti bil-gotta.